A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

BACKGROUND: Prevention of unnecessary biopsies and overtreatment of indolent disease remains a challenge in the management of prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk and high-risk) diseases are needed to improve risk stratification and mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fang, Olkhov-Mitsel, Ekaterina, Kamdar, Shivani, Jeyapala, Renu, Garcia, Julia, Hurst, Rachel, Hanna, Marcelino Yazbek, Mills, Robert, Tuzova, Alexandra V., O’Reilly, Eve, Kelly, Sarah, Cooper, Colin, Brewer, Daniel, Perry, Antoinette S., Clark, Jeremy, Fleshner, Neil, Bapat, Bharati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260648/
https://www.ncbi.nlm.nih.gov/pubmed/30470249
http://dx.doi.org/10.1186/s13148-018-0575-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260648/
https://www.ncbi.nlm.nih.gov/pubmed/30470249
http://dx.doi.org/10.1186/s13148-018-0575-z

Ejemplares similares